Toggle Health Problems and D

Optic neuritis progession into Multiple Sclerosis reduced 68 percent by 50,000 IU of vitamin D weekly

Update Oct 2017: Clinical trial being started for Optic Neuritis and Vitamin D: 50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days Results are due 2023

Optic neuritis progession into Multiple Sclerosis reduced 68 % by 50,000 IU of vitamin D weekly- 2013

Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial
Acta Neurol Belg. 2013 Sep;113(3):257-63. doi: 10.1007/s13760-012-0166-2. Epub 2012 Dec 19.
Derakhshandi H 1, Etemadifar M, Feizi A, Abtahi SH, Minagar A, Abtahi MA, Abtahi ZA, Dehghani A, Sajjadi S, Tabrizi N.
1 Isfahan Eye Research Center (IERC), Feiz Hospital, Isfahan University of Medical Sciences, SHARNOS Co. No. 9, Boroomand. Seyed-Alikhan, Chaharbagh Abbasi, 81448-14581, Isfahan, Iran.

Multiple sclerosis (MS) presents with optic neuritis (ON) in 20 % of cases and 50 % of ON patients develop MS within 15 years. In this study, we evaluated the preventive effects of vitamin D3 administration on the conversion of ON to MS (primary outcome) and on the MRI lesions (secondary outcome) of ON patients with low serum 25 (OH) D levels. Thirty ON patients (15 in each of 2 groups, aged 20-40 years) with serum 25 (OH) D levels of less than 30 ng/ml were enrolled in a double blind, randomized, parallel-group trial. The treatment group (cases) received 50,000 IU of vitamin D3 weekly for 12 months and the control group (controls) received a placebo weekly for 12 months. Finally, the subsequent relapse rate and changes in MRI plaques were compared between the two groups.

Risk reduction was 68.4 % for the primary outcome in the treatment group (relative risk = 0.316, p = 0.007).

After 12 months, patients in the treatment group had a significantly lower incidence rate of cortical, juxtacortical, corpus callosal, new T2, new gadolinium-enhancing lesions and black holes.

The mean number of total plaques showed a marginally significant decrease in the group receiving vitamin D3 supplementation as compared with the placebo group (p = 0.092). Administration of vitamin D3 supplements to ON patients with low serum vitamin 25 (OH) D levels may delay the onset of a second clinical attack and the subsequent conversion to MS.

PMID: 23250818 Publisher charges $40 for PDF checked Sept 2017

A prospective cohort study of vitamin D in optic neuritis recovery - 2017

Mult Scler. 2017 Jan;23(1):82-93. doi: 10.1177/1352458516642315. Epub 2016 Jul 11.
Burton JM1, Eliasziw M2, Trufyn J3, Tung C4, Carter G5, Costello F6.
1 Dept of Clinical Neurosciences and Department of Community Health Sciences, Hotchkiss Brain Institute, U. of Calgary, Calgary, AB, Canada.
2 Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA.
3 Neurosciences Graduate Program, University of Calgary, Calgary, AB, Canada.
4 Biological Sciences Undergraduate Sciences Program, University of Calgary, Calgary, AB, Canada.
5 Eye Clinic, Rockyview General Hospital, Calgary, AB, Canada.
6 Dept of Clinical Neurosciences and Department of Surgery (Ophthalmology), Hotchkiss Brain Institute, U. of Calgary, Calgary, AB, Canada.

Vitamin D sufficiency is associated with better inflammatory outcomes in multiple sclerosis (MS). We hypothesize that it is also associated with better long-term neurodegenerative measures.

To show that vitamin D sufficient patients (25-hydroxy vitamin D (25(OH)D) > 80 nmol/L) have better optical coherence tomography (OCT) neuroaxonal measures of ganglion cell layer (GCL) and retinal nerve fiber layer (RNFL) thickness after optic neuritis.

In this prospective cohort study, acute optic neuritis patients underwent OCT and serum 25(OH)D assessments at baseline and at month 6, with comparisons between vitamin D sufficient and insufficient patients, and men and women. Potential confounding variables were evaluated.

Of 49 enrolled, 36 had complete, analyzable data. At baseline, vitamin D insufficiency was associated with greater RNFL thickness (134.3 vs. 95.2 µm; p = 0.003) in affected eyes. At month 6, insufficient patients had greater GCL thinning (GCL inter-eye difference: 14.2 vs. 4.0 µm, p = 0.008). Men had greater RNFL and GCL thinning than women (GCL: 61.2 vs. 69.6 µm, p = 0.036).

Acutely, in optic neuritis, RNFL thickness is increased with vitamin D insufficiency. Chronically, neuronal, and possibly axonal loss are associated with vitamin D insufficiency and male gender, suggesting vitamin D and female gender may confer neuroprotection in optic neuritis, and possibly, central nervous system (CNS) inflammatory disease.

PMID: 27037181 DOI: 10.1177/1352458516642315

See also VitaminDWiki

Overview MS and vitamin D contains the following summary
Clinical interventions have shown that Vitamin D can prevent, treat, and even cure Multiple Sclerosis, at a tiny fraction of the cost of the drugs now used to treat it, and without side effects.

Summary: lack of consensus on how much to prevent, treat, or cure MS.

See any problem with this page? Report it (WORKS NOV 2021)